Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)

Inclusion Criteria:

• Successful completion of ACTG Protocol A5211, or favorable response in A5211 butdiscontinued due to tropism shift, or screened for A5211 and met inclusion/exclusioncriteria but unable to enroll due to protocol closure.
• Participants must also be on a ritonavir-containing antiretroviral regimen at entry,and have acceptable hematologic and laboratory parameters.
• Female participants of reproductive potential must agree to use 2 reliable methods ofcontraception, including a barrier method, and must have a negative urine pregnancytest prior to dosing.

Exclusion Criteria:

• History of seizure or drug use that increases risk of seizure, current use of CYP3A4inducers, prior history of malignancy, active drug or alcohol use or dependence thatwould interfere with study requirements
• Female participants who are breast-feeding, pregnant, or plan to become pregnant
• Participation in a clinical trial with another investigational drug.
• Participants with serious illness requiring systemic therapy and/or hospitalizationmust not begin VCV (if not already on VCV) until participant completes therapy or isclinically stable on therapy for at least 14 days prior to enrollment.